PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.71%
G&A growth 50-75% of GNPX's 52.68%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
-38.54%
Other expenses reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine efficiency.
25.41%
Operating expenses growth 1.25-1.5x GNPX's 17.95%. Martin Whitman would scrutinize control.
25.41%
Total costs growth 1.25-1.5x GNPX's 17.95%. Martin Whitman would scrutinize control.
-10.64%
Interest expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
353.66%
Other expenses growth above 1.5x GNPX's 46.73%. Michael Burry would check for concerning trends.
100.00%
Pre-tax income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-610.74%
Tax expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
610.74%
Net income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
609.26%
EPS growth exceeding 1.5x GNPX's 34.62%. David Dodd would verify competitive advantages.
609.26%
Diluted EPS growth exceeding 1.5x GNPX's 34.62%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.